TherapeuticsMD Up 40% After Mixed Q3, Plans To Resubmit NDA For TX-004HR

TherapeuticsMD Inc TXMD shares are trading higher by $1.79 (39.8 percent) at $6.15 in Monday's session.

Before the open, the company reported a mixed Q3 report that beat for EPS but missed for sales by $8.1 million.

Investors appear to be encouraged by the news that the company plans to resubmit NDA for TX-004HR, for women with moderate-to-severs vaginal pain during intercourse.

After a higher, TherapeuticsMD retreated but immediately found support at $5.94 and continued its move higher. The ensuing rally took the stock to $6.85, which marks its highest level since it peaked on Sept. 7 at $7.01. Since reaching that level, it has been drifting back towards the low for the session, but has yet to make one as of 12:40 p.m. EST.